Lavilla Olleros, 14,921 patient HCQ late treatment study: 36% lower mortality [p<0.0001] https://c19p.org/lavillaolleros
copied to clipboard
Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19
et al., PLOS ONE, doi:10.1371/journal.pone.0261711
Retrospective 14,921 hospitalized patients in Spain, showing lower mortality with HCQ treatment.
|
risk of death, 36.2% lower, RR 0.64, p < 0.001, treatment 2,285 of 12,772 (17.9%), control 774 of 2,149 (36.0%), NNT 5.5, adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lavilla Olleros et al., 21 Jan 2022, retrospective, Spain, peer-reviewed, 22 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.